TRANSLATIONAL MEDICINEﾠFORUMﾠ2007ﾠAGENDA

Defining Success in Translational Medicine

SUNDAY, SEPTEMBER 9, 2007

4:00 - 6:00pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Forum registration
Regency Room

5:00 ﾖ 6:30pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Opening reception
Poolside Patio

6:30pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Sponsors Dinner (invitation only)
Bus Loading at Lindell Avenue Entrance

7:00 ﾖ 9:00pmﾠﾠﾠﾠﾠﾠﾠ ﾠ ﾠﾠ Sponsors Dinner (invitation only) ﾠﾠ
SqWires Restaurant
1415 South 18th Street - parking lots located on both sides of street

MONDAY, SEPTEMBER 10, 2007

7:00amﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Registration & Continental Breakfast
Khorassan West

8:00 - 8:30amﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Welcome
Khorassan East

Welcome
Marcia Mellitz, President & CEO, Center for Emerging Technologies

Morrie Ruffin, Chief Executive Officer, LifeTech Innovations

Introductory Remarks
Lesa Mitchell,ﾠ Vice President, Advancing Innovation, Kauffman Foundation

Larry Shapiro, Executive Vice Chancellor for Medical Affairs & Dean, Washington University School of Medicine

Mark Wrighton, Chancellor, Washington University

8:30 ﾖ 10:00am ﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Plenary Session

Bucking Conventional Wisdom: How Can We Prepare for the Challenges & Opportunities of Personalized Medicine?

Moderator: Phil Needleman, Chief Scientist & Senior Executive Vice President, PharmaciaﾠCorp. (retired)

Panelists: Amy Brower, Executive Director of Medical Informatics & Genetics, Third Wave Technologies

William Greenlee, President & CEO, The Hamner Institutes for Health Sciences

Isaac Kohane, Henderson Associate Professor of Pediatrics & Health Sciences & Technology, Harvard Medical School

Lucy Lu, Vice President, Technology Management, Roche Diagnostics

Rick Wilson, Director of the Genome Sequencing Center, Washington University

The process by which we discover, optimize, develop, manufacture and market new medicines is fundamentally changing. Some believe this will lead to more efficient, targeted treatment regimens ultimately creating a more vibrant, responsive and robust healthcare economy.ﾠ Others say these changes will cause a fundamental shift in the economics of drug development and could severely dampen investor enthusiasm in the industry.

If the real future lies somewhere in between, what can the major stakeholders in translational medicine do to encourage adoption of systems and processes that will accelerate the rate of innovation towards a more efficient therapeutic development model?

The Changing Landscape: New Models for Funding Translational Research

Moderator: Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation

Panelists: Robert Beall, President & CEO, Cystic Fibrosis Foundation

Deborah Brooks, Co-Founder, Michael J. Fox Foundation

Laura Heisler, Intellectual Property Manager, Wisconsin Alumni Research Foundation (WARF)

Jamie Heywood, Founding Director of d'Arbeloff & Former CEO, ALS Therapy Development Institute

Dennis Purcell, Senior Managing Director, Aisling Capital

Robert Zivin, Corporate Director, Corporate Office of Science & Technology, Johnson & Johnson

Disease foundations and other non-industry, non-government sources now playﾠaﾠcriticalﾠroleﾠin funding and supporting early-stage research.ﾠ Explore some of the newer investment models that support breakthrough translational medicine and the issues involved in meshing diverse sources of funds with differing agendas.

As major research universities diversify their funding base beyond dependence on RO1s, how can they find other sources of funding for their most promising research? What are these sources of funding -- foundations, corporate sponsors, public and private investment funds?ﾠ How do we reconcile near-term return objectives with philanthropic objectives?

ﾠ

12:00 ﾖ 1:30pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Lunch
Khorassan East

Roundtable of National Leaders: Future of Medicine: Can the modern healthcare economy adapt to accelerating technological change?

Moderator: William Peck, Director, Center for the Study of Health Policy, Washington University

Panelists: Peter Corr, Corporate Senior Vice President for Science & Technology, Pfizer Inc. (retired)

Harlan Krumholz, Harold H. Hines, Jr. Professor of Medicine, Epidemiology & Public Health, and Director, Robert Woods Johnson Clinical Scholars Program, Yale University

Garry Neil, Group President of the CNS-IM Franchise, Johnson & Johnson Pharmaceuticals Development Corp.

Ralph Snyderman, Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine, Duke University School of Medicine

Roundtable 1:ﾠ Institutional Policy & Practice Supporting Translational Research
Empire Room

Moderator: Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation

Panelists: Katharine Ku, Director of the Office of Technology Licensing, Stanford University

Jose Olivares, Deputy Division Leader, Bioscience Division, Los Alamos National Laboratory

John Parrish, Director & Founder, Center for Integration of Medicine & Innovative Technology (CIMIT)

Tom Stossel, American Cancer Society Professor of Medicine, Harvard Medical School & Director, Translational Medicine Division, Brigham & Women's Hospital

Robert Taber, Vice Chancellor of Corporate & Venture Development, Duke University

What is the best measure of the success of a research institution's commercialization strategy: number of disclosures, patents, licenses or companies created?ﾠ Examine the strategies of many of the leading institutions that are funding translational research and commercializing technology.ﾠ Where does translational medicine work best?ﾠ What are the greatest challenges? What is the best framework for managing the IP, handling material transfer agreements, and determining the direction of the research?ﾠ What are the best ways to encourage and work with entrepreneurial faculty,ﾠcreate and fund start-up companies from university technology, and effectively use internal and external translational research funds?

Roundtable 2: Neurodegenerative Diseases
Lenox Room

Moderator: Mark Goldberg, Director of the Hope Center for Neurological Disorders, Washington University

Panelists: Marc Cochran, CEO & Executive Director, Blanchette Rockefeller Neurosciences Institute

Gene Johnson, Professor of Neurology, and of Molecular Biology & Pharmacology, Washington University

Karl Kieburtz, Professor of Neurology and of Community & Preventive Medicine, University of Rochester Medical Center

Eric Siemers, Medical Director, Alzheimer's Disease Team, Eli Lilly and Company

James Wang, Vice President of Discovery Sciences, High Q Foundation

Roundtable 3: Cardiovascular
Plaza Room

Moderator: Dennis Wahr, RiverVest Venture Partners

Panelists: Alan Bentley, Director of Commercialization, Cleveland Clinic

Joel Braunstein, CEO, LifeTech Research

Harlan Krumholz, Professor of Medicine, Epidemiology & Public Health, Yale University

Achi Ludomirsky, Pediatrics & Biomedical Engineering, St. Louis Children's Hospital

Jerry Millhon, Executive Director, Pacific Vascular Research Foundation

Disease and technology focused sessions will explore translational research models in practice in thirteenﾠdifferentﾠresearch disciplines. Each session will be led by a top researcher who will initiate discussion around a number of topics related to the major issues involved in supporting successful translational research.

Several investigators will be invited to briefly summarize their research and talk about their strategies for moving their work towards clinical development and commercialization.ﾠ

3:15 ﾖ 3:45pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Networking Break
Conference Center

3:45 ﾖ 5:30pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Concurrent Issue & Disease Roundtable Sessions

Roundtable 4: Collaborative Models in Translational Research
Empire Room

Moderator: Frank Douglas, Founder & First Executive Director, MIT Center for Biomedical Innovation

Panelists: Anthony Atala, W.H. Boyce Professor & Director of the Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine

Donald Lombardi, CEO, Pediatric Innovation Institute

Art Mellor, President, Accelerated Cure Project for Multiple Sclerosis

Scott Santarella, COO, Multiple Myeloma Research Foundation & Multiple Myeloma Research Consortium

Sam Wickline, Director, Siteman Center for Cancer Nanotechnology Excellence, Washington University

More effective models to support translational medicine will largely depend on collaborative research structures that leverage research activities across multiple institutions. How do we promote more multi-institutional and university-company collaborations?

Examine some of the existing collaborative research models and theirﾠinherentﾠbenefits and challenges:ﾠ How should we fund pre-competitive collaborative research? Are industry and/or foundation supported research consortia the most effective way to produce pre-competitive discoveries (e.g., biomarkers, validated targets, toxicity studies, molecular libraries, etc.)?ﾠ How should we manage tissue banks and associated medical histories; identification and standardization of biomarkers; and other collaborative research tools?ﾠ

Roundtable 5: Rare Diseases
Lenox Room

Moderator: Brian Clevinger, Founder & Managing Director, Prolog Ventures

Panelists: Robert Beall, President & CEO, Cystic Fibrosis Foundation

Rashmi Gopal-Srivastava, Director of Extramural Research Program, Office of Rare Diseases, National Institutes of Health

Jamie Heywood, Founding Director of d'Arbeloff & Former CEO, ALS Therapy Development Institute

Jon LeBowitz, CSO, ZyStor Therapeutics

Stuart Peltz, President & CEO, PTC Therapeutics

Roundtable 6: Devices
Plaza Room

Moderator: Philippe Sommer, Director of Entrepreneurship Programs, Batten Institute, University of Virginia

Panelists: Janice Crosby, Director, Business Development, CIMIT

John Linehan, Consulting Professor of Bioengineering, Program in Biodesign, Stanford University

Banu Onaral, H. H. Sun Professor of Biomedical Engineering & Electrical Engineering, Drexel University

Tom Skalak, Professor & Chair of the Department of Biomedical Engineering, University of Virginia

6:30 ﾖ 10:00pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Reception & Dinner ﾠﾠﾠﾠ

6:30pm
Bus Loading at Lindell Avenue Entrance

7:00 - 10:00pm
Lakeside Caf￩, St. Louis Zoo

Attendees will sign-up to sit at a table hosted by a noted individual in science, industry, government, philanthropy or investment.

TUESDAY, SEPTEMBER 11, 2007

7:00amﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Continental Breakfast
Khorassan West

8:00 ﾖ 9:15amﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Plenary Session
Khorassan East

Partnering Effectively with Industry

Moderator: David Rosen, Developmental & Commercial Head of Strategic Alliances, Pfizer Inc.

Panelists: Joni Catalano-Sherman, Corporate Director, Science & Technology, Johnson & Johnson J-C Health Care Ltd.

Joyce Cramer, President, Epilepsy Therapy Development Project

Stuart Peltz, President & CEO, PTC Therapeutics

Ward Peterson, Vice President of Research & Preclinical Development, Inspire Pharmaceuticals

Tom Skalak, Professor & Chair of the Department of Biomedical Engineering, University of Virginia

Most experts acknowledge that if we are to improve the productivity of drug discovery and development systems globally, we need to develop more effective ways of directing industry experience and resources towards the earliest stages ﾖ the university.ﾠ

What are the most successful models for industry-sponsored research?ﾠ How do we assess the value of untargeted verses targeted corporate funding of university research?ﾠ Can industry play a more active role in translational research without stifling the innovative culture? Can development-stage programs be managed in a university setting through proof of concept?ﾠ What are best practices for win-win structures for university-industry collaborations?ﾠﾠ

9:30 ﾖ 11:00am ﾠ ﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Concurrent Disease & Technology Roundtable Sessions

Roundtable 7: Cancer: Solid Tumors
Empire Room ﾠﾠﾠﾠ

Moderator: Dan Perry, Executive Director, Alliance for Aging Research

Panelists: Borje Andersson, Professor of Stem Cell Transplantation & Cellular Therapy, MD Anderson School of Medicine, University of Texas

John DiPersio, Deputy Director, Alvin J. Siteman Cancer Center, and Chief, Division of Oncology, Washington University School of Medicine

Stephen Gately, CSO, TGen Drug Development Services (TD2)

Dan Rhodes, Co-Founder & CSO, Compendia Biosciences

Dominic Spinella, Head of Translational Medicine, Pfizer Oncology

Roundtable 8: Regenerative Medicine
Lenox Roomﾠ

Moderator: Kathryne Carr, Managing Director, Tall Oaks Capital Partners

Panelists: Anthony Atala, W.H. Boyce Professor & Director of the Wake Forest Institute for Regenerative Medicine, Wake Forest University

Barbara Boyan, Price Gilbert Jr. Chair in Tissue Engineering, Georgia Institute of Technology

Joe Feder, Chairman, ISTO Technologies Inc.

Marc Penn, Medical Director of the Cardiac Intensive Care Unit, Cleveland Clinic

Buddy Ratner, Director, University of Washington Engineered Biomaterials (UWEB) Engineering Research Center, University of Washington

Roundtable 9: Instruments & Tools
Plaza Roomﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ

Moderator: Ravi Kiron, Chief Operating Officer, LifeTech Research

Panelists: Larry DeLucas, Director of the Center for Biophysical Sciences & Engineering, University of Alabama at Birmingham

Philippe Goix, CEO, Singulex

Doug McNair, Senior Vice President of Research & Development, Cerner Corporation

John Wilbanks, Vice President, Science, Creative Commons

11:00am ﾖ 12:30pmﾠﾠﾠﾠﾠﾠﾠﾠ Concurrent Disease &ﾠTechnology Roundtable Sessions

Roundtable 10: Alzheimer's

Empire Room

Moderator: David Holtzman, Associate Director of the Alzheimer's Disease Research Center and Chair of Neurology, Washington University

Panelists: Tim Armour, President & CEO, Cure Alzheimer's Fund

Corinne Augelli-Szafran, Director of Laboratory of Experimental Alzheimer Drugs (LEAD), Harvard Medical School & Brigham and Women's Hospital

Todd Golde, Professor and Chair of the Department of Neurosciences, Mayo Clinic

John Morris, Director of the Memory and Aging Project, Washington University

Adam Simon, Division of Virus & Cellular Biology, Merck Research Laboratories, Merck & Co.

Roundtable 11: Inflammation & Autoimmune Diseases

Lenox Room

Moderator: Daniel Getman, Vice President of Global Research & Development, and Director of the St. Louis Laboratories, Pfizer Inc.

Panelists: Richard Brasington, Director of Clinical Rheumatology, Washington University School of Medicine

Ivan Plavec, Vice President, Technology & Alliances, BioSeek

Ronenn Roubenoff, Senior Director of Immunology Medical Research, Biogen Idec

Walter Smith, Executive Director, Inflammation Pathways, Pfizer Global Research & Development

Max Wallace, CEO, Theralogics

Roundtable 12: Discovery Platforms: RNAi, siRNA, microRNA & Nano Medicine
Plaza Room

Moderator: Gary Davis, Manager of Genomics in Biotechnology R&D Division, Sigma-Aldrich Corporation

Panelists: Robert Forgey, COO, ProNAi Therapeutics Inc.

Afshin Ghavami, Director of Research, PsychoGenics Inc.ﾠ

Dennis Riley, Senior Vice President of R&D, Kereos Inc.

Peter Welch, R&D Director of Gene Expression Profiling, Invitrogen Corporation

12:45 ﾖ 1:45pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Lunch -- Defining Success in Translational Medicine
Khorassan East

Discussion Leaders:

Anna Barker, Deputy Director for Advanced Technologies & Strategic Partnerships, National Cancer Institute, National Institutes of Health

GregﾠSimon, President, FasterCures

ﾠ

2:00 ﾖ 3:30pmﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ Concurrent Disease & Technology Roundtable Sessions

Roundtable 13: Diabetes
Lenox Room

Moderator: Katherine Gordon, Director of Business Development, Office of Technology Development, Harvard Medical School

Panelists: Denise Faustman, Director, Immunology Labs, Massachusetts General Hospital

Samuel Klein, Chief of the Division of Geriatrics & Nutritional Sciences, Washington University School of Medicine

William Lowe, Interim Chair, Department of Medicine, Northwestern University

Leslie Molony, Co-Founder, President & CEO, Transgeneron Therapeutics, Inc.

Roundtable 14: Infectious Disease
Plaza Room ﾠﾠﾠﾠ

Moderator: Sam Stanley, Vice Chancellor for Research, Washington University

Panelists: Robert Belshe, Director & Professor, Division of Infectious Diseases and Immunology, Saint Louis University

Praveen Tipirneni, Head of Corporate & Business Development, Cubist Pharmaceuticals

Geoff Waldo, Technical Staff in Biosciences, Los Alamos National Laboratory

Roundtable 15: Cancer: Hematologic
Empire Room ﾠﾠﾠﾠﾠﾠﾠﾠﾠﾠ

Moderator: Edward Allera, Managing Shareholder, Buchanan, Ingersoll & Rooney

Panelists: Camille Abboud, Professor of Medicine, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine

Anthony Letai, Clinician & Researcher of Hematologic Oncology, Medical Oncology & Hematologic Neoplasia, Dana-Farber Cancer Institute, Harvard Medical School

David Livingston, Senior Vice President of Biology & Head of Biodetection, Ensemble Discovery Corporation

Linda JZ Penn, Head Division of Cancer Genomics & Proteomics, Ontario Cancer Institute